Krystal Biotech Q2 EPS Forecast Increased by William Blair

Krystal Biotech, Inc. (NASDAQ:KRYS) – Analysts at William Blair lifted their Q2 2025 EPS estimates for Krystal Biotech in a note issued to investors on Monday, November 4th. William Blair analyst S. Corwin now anticipates that the company will earn $1.59 per share for the quarter, up from their prior estimate of $1.33. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.88 per share. William Blair also issued estimates for Krystal Biotech’s FY2026 earnings at $4.91 EPS and FY2027 earnings at $8.39 EPS.

A number of other research analysts have also recently commented on KRYS. Evercore ISI upped their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Stifel Nicolaus upped their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday. Chardan Capital upped their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $197.00.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $183.09 on Thursday. The firm’s 50-day moving average is $181.39 and its two-hundred day moving average is $180.25. Krystal Biotech has a 12 month low of $93.95 and a 12 month high of $219.34. The stock has a market capitalization of $5.26 billion, a P/E ratio of 103.44 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same quarter in the prior year, the firm posted ($0.67) earnings per share. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KRYS. EFG Asset Management North America Corp. grew its position in shares of Krystal Biotech by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after buying an additional 60 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after purchasing an additional 94 shares during the last quarter. Arizona State Retirement System boosted its position in shares of Krystal Biotech by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock valued at $945,000 after purchasing an additional 108 shares during the period. Finally, Fiera Capital Corp grew its stake in Krystal Biotech by 0.8% during the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after buying an additional 130 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).